Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRISNASDAQ:DOMHNASDAQ:FBIONASDAQ:VICL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRISCuris$2.25+7.7%$1.79$1.02▼$10.99$23.54M3.6571,260 shs134,543 shsDOMHDominari$4.59-2.8%$4.62$0.83▼$13.58$67.22M0.591.23 million shs397,013 shsFBIOFortress Biotech$1.95+2.6%$1.65$1.33▼$2.89$57.66M1.85408,114 shs213,206 shsVICLVical$1.24$0.60▼$1.47$21.01M0.321.44 million shs35,024 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRISCuris+7.66%+13.07%+24.31%-25.00%-78.77%DOMHDominari-2.75%-3.16%-1.71%-41.15%+88.89%FBIOFortress Biotech+2.63%+12.72%+11.43%+24.20%+7.14%VICLVical0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRISCuris3.0869 of 5 stars3.55.00.00.02.80.01.3DOMHDominari0.9724 of 5 stars0.02.00.00.03.02.50.6FBIOFortress Biotech2.6959 of 5 stars3.51.00.00.03.33.30.6VICLVicalN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRISCuris 3.00Buy$17.00655.56% UpsideDOMHDominari 0.00N/AN/AN/AFBIOFortress Biotech 3.00Buy$21.00976.92% UpsideVICLVical 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest VICL, DOMH, FBIO, and CRIS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025CRISCurisHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$17.003/31/2025CRISCurisHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$20.00 ➝ $16.003/11/2025FBIOFortress BiotechRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $16.00(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRISCuris$11.20M2.10N/AN/A$3.34 per share0.67DOMHDominari$24.89M2.70N/AN/A$9.90 per share0.46FBIOFortress Biotech$57.78M1.00N/AN/A$0.10 per share19.50VICLVical$1.62M0.00N/AN/A$1.82 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRISCuris-$47.41M-$6.23N/AN/AN/A-443.35%-923.37%-78.35%8/7/2025 (Estimated)DOMHDominari-$22.88M-$4.50N/A∞N/A-180.22%-32.89%-29.47%8/6/2025 (Estimated)FBIOFortress Biotech-$60.64M-$2.23N/AN/AN/A-84.53%N/A-34.93%8/12/2025 (Estimated)VICLVical-$16.25M-$0.81N/AN/AN/A-1,002.10%-29.46%-27.85%N/ALatest VICL, DOMH, FBIO, and CRIS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025CRISCuris-$1.14-$1.25-$0.11-$1.25$2.37 million$2.38 million4/15/2025Q4 2024DOMHDominariN/A$0.20N/A$0.20N/A$6.56 million3/31/2025Q4 2024CRISCuris-$1.36-$1.25+$0.11-$1.25$2.04 million$2.70 million3/31/2025Q4 2024FBIOFortress Biotech-$0.79-$0.26+$0.53-$0.26$16.30 million$15.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRISCurisN/AN/AN/AN/AN/ADOMHDominariN/AN/AN/AN/AN/AFBIOFortress BiotechN/AN/AN/AN/AN/AVICLVicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRISCurisN/A1.221.22DOMHDominariN/A10.2510.25FBIOFortress BiotechN/A1.231.06VICLVicalN/A36.8436.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRISCuris29.97%DOMHDominari42.48%FBIOFortress Biotech96.51%VICLVical29.06%Insider OwnershipCompanyInsider OwnershipCRISCuris5.45%DOMHDominari32.98%FBIOFortress Biotech33.40%VICLVical4.58%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRISCuris6010.46 million7.98 millionNo DataDOMHDominari414.64 million4.01 millionNot OptionableFBIOFortress Biotech17029.57 million18.39 millionOptionableVICLVical3022.84 millionN/ANot OptionableVICL, DOMH, FBIO, and CRIS HeadlinesRecent News About These CompaniesMattr introduces VICAL Viewer to ease mDL adoption for relying partiesSeptember 11, 2024 | biometricupdate.comVical Announces Review of Potential Strategic TransactionsAugust 17, 2024 | br.advfn.comVical Reports Third Quarter 2018 Financial and Operational ResultsAugust 17, 2024 | br.advfn.comFresh Tracks Therapeutics (FRTX) Earnings Dates & ReportsMay 26, 2024 | investing.comEvan Gershkovich’s sister was the quiet one. Now she’s his voice.March 29, 2024 | msn.comVideo: Travis Kelce’s Friends Attempt to Distract Him in Golf by Playing Taylor Swift’s SongMarch 29, 2024 | ijr.comSong Suffragettes celebrates 10 years with Wynonna, female country chart-toppers, moreMarch 29, 2024 | msn.comSong lyrics getting simpler, more repetitive, angry and self-obsessed – studyMarch 29, 2024 | theguardian.comBeyoncé’s Younger Daughter Rumi Carter Joins Her on New Song ‘Protector’March 29, 2024 | msn.comBeyoncé features Shaboozey on her song 'Spaghettii': Who is the hip-hop, country artist?March 29, 2024 | msn.comCreed frontman Scott Stapp on singing his 'life story,' moving to Nashville and finding a dream teamMarch 28, 2024 | msn.comBBC stands by replacing singer with AI-generated voiceMarch 28, 2024 | msn.comSong Lyrics Really Are Getting Simpler and More Repetitive, Study FindsMarch 28, 2024 | scientificamerican.comFunniest misheard Beyoncé lyrics, from 'Singing lettuce' to 'No bottom knee'March 28, 2024 | msn.comKanye wife Bianca Censori’s voice heard for first time in newly resurfaced videoMarch 28, 2024 | nydailynews.comTop 'American Idol' and 'The Voice' contestants come from these states: Where Tennessee ranks in the listMarch 28, 2024 | tennessean.comSong Lyrics Are Now More Repetitive and Simple, Study ConfirmsMarch 28, 2024 | msn.comKJP Declares Press Gaggle off the Record as Obama’s Voice Is HeardMarch 28, 2024 | ijr.comSong lyrics have become angrier since the 80s, study showsMarch 28, 2024 | msn.comBoston Red Sox minor league pitcher, former Navy standout Noah Song set to undergo Tommy John surgeryMarch 28, 2024 | baltimoresun.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVICL, DOMH, FBIO, and CRIS Company DescriptionsCuris NASDAQ:CRIS$2.25 +0.16 (+7.66%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$2.17 -0.08 (-3.33%) As of 05/29/2025 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.Dominari NASDAQ:DOMH$4.59 -0.13 (-2.75%) As of 05/29/2025 04:00 PM EasternDominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.Fortress Biotech NASDAQ:FBIO$1.95 +0.05 (+2.63%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$1.96 +0.02 (+0.77%) As of 05/29/2025 05:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.Vical NASDAQ:VICLVical Incorporated researches and develops biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company was founded in 1987 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
